New bladder cancer drug could spare patients from bladder removal
Disease control
Not yet recruiting
This Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…
Phase: PHASE3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC